Format
Sort by
Items per page

Send to

Choose Destination

Best matches for D’Incalci M[au]:

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Germano G et al. Nature. (2017)

Not only tumor but also therapy heterogeneity. Garattini S et al. Ann Oncol. (2018)

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Germano G et al. Clin Colorectal Cancer. (2018)

Search results

Items: 1 to 50 of 508

1.

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.

Petrillo M, Zucchetti M, Cianci S, Morosi L, Ronsini C, Colombo A, D'Incalci M, Scambia G, Fagotti A.

J Gynecol Oncol. 2019 Mar 1. doi: 10.3802/jgo.2019.30.e59. [Epub ahead of print]

2.

Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.

Ballabio S, Craparotta I, Paracchini L, Mannarino L, Corso S, Pezzotta MG, Vescio M, Fruscio R, Romualdi C, Dainese E, Ceppi L, Calura E, Pileggi S, Siravegna G, Pattini L, Martini P, Delle Marchette M, Mangioni C, Ardizzoia A, Pellegrino A, Landoni F, D'Incalci M, Beltrame L, Marchini S.

Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288. [Epub ahead of print]

PMID:
30892690
3.

Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.

Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, D'Incalci M, Cortelezzi A, Zucchetti M.

Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14. No abstract available.

4.

Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.

Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology.

J Neurooncol. 2019 May;142(3):455-462. doi: 10.1007/s11060-019-03116-z. Epub 2019 Feb 6.

PMID:
30726533
5.

Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma.

Carminati L, Pinessi D, Borsotti P, Minoli L, Giavazzi R, D'Incalci M, Belotti D, Taraboletti G.

Carcinogenesis. 2019 Apr 29;40(2):303-312. doi: 10.1093/carcin/bgy177.

PMID:
30544170
6.

Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging.

Falcetta F, Morosi L, Ubezio P, Giordano S, Decio A, Giavazzi R, Frapolli R, Prasad M, Franceschi P, D'Incalci M, Davoli E.

Anal Chim Acta. 2018 Dec 26;1042:1-10. doi: 10.1016/j.aca.2018.06.067. Epub 2018 Jun 28.

PMID:
30428975
7.

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.

Rulli E, Ghilotti F, Biagioli E, Porcu L, Marabese M, D'Incalci M, Bellocco R, Torri V.

Br J Cancer. 2018 Dec;119(12):1456-1463. doi: 10.1038/s41416-018-0302-8. Epub 2018 Nov 13.

PMID:
30420618
8.

Drug-Homogeneity Index in Mass-Spectrometry Imaging.

Prasad M, Postma G, Morosi L, Giordano S, Giavazzi R, D'Incalci M, Falcetta F, Davoli E, Jansen J, Franceschi P.

Anal Chem. 2018 Nov 20;90(22):13257-13264. doi: 10.1021/acs.analchem.8b01870. Epub 2018 Nov 8.

PMID:
30359532
9.

Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.

Frassanito MA, Desantis V, Di Marzo L, Craparotta I, Beltrame L, Marchini S, Annese T, Visino F, Arciuli M, Saltarella I, Lamanuzzi A, Solimando AG, Nico B, De Angelis M, Racanelli V, Mariggiò MA, Chiacchio R, Pizzuti M, Gallone A, Fumarulo R, D'Incalci M, Vacca A.

J Pathol. 2019 Feb;247(2):241-253. doi: 10.1002/path.5187.

PMID:
30357841
10.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M.

Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.

PMID:
30217671
11.

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.

Gadducci A, Grosso F, Scambia G, Raspagliesi F, Colombo N, Grignani G, Casali P, Sanfilippo R, Buonadonna A, Santoro A, Bruzzone M, Artioli G, Lorusso D, Biagioli E, Fossati R, Galli F, Negri E, Rulli E, Torri V, D'Incalci M.

Br J Cancer. 2018 Aug;119(5):565-571. doi: 10.1038/s41416-018-0190-y. Epub 2018 Jul 30.

PMID:
30057406
12.

Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients.

Capasso Palmiero U, Morosi L, Lupi M, Ponzo M, Frapolli R, Zucchetti M, Ubezio P, Morbidelli M, D'Incalci M, Bello E, Moscatelli D.

Macromol Biosci. 2018 Oct;18(10):e1800164. doi: 10.1002/mabi.201800164. Epub 2018 Jul 25.

PMID:
30047229
13.

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.

Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, Del Bufalo D, Milella M, Biagini R, D'Incalci M, Falcioni R.

Oncogene. 2018 Nov;37(45):5926-5938. doi: 10.1038/s41388-018-0394-x. Epub 2018 Jul 6.

14.

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB.

Camorani S, Cerchia L, Fedele M, Erba E, D'Incalci M, Crescenzi E.

Oncotarget. 2018 Apr 13;9(28):19929-19944. doi: 10.18632/oncotarget.24961. eCollection 2018 Apr 13.

15.

Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.

Spriano F, Chung EY, Panini N, Cascione L, Rinaldi A, Erba E, Stathis A, D'Incalci M, Bertoni F, Gatta R.

Br J Haematol. 2019 Mar;184(6):1022-1025. doi: 10.1111/bjh.15212. Epub 2018 Apr 2. No abstract available.

PMID:
29611184
16.

Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin.

Capasso Palmiero U, Morosi L, Bello E, Ponzo M, Frapolli R, Matteo C, Ferrari M, Zucchetti M, Minoli L, De Maglie M, Romanelli P, Morbidelli M, D'Incalci M, Moscatelli D.

J Control Release. 2018 Apr 28;276:140-149. doi: 10.1016/j.jconrel.2018.03.005. Epub 2018 Mar 7.

PMID:
29524443
17.

Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.

Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, Murgia A, Sanges F, Pira G, Manca A, Palmas D, Floris M, Asunis AM, Atzori F, Carru C, D'Incalci M, Ghiani M, Marras V, Onnis D, Santona MC, Sarobba G, Valle E, Canu L, Cossu S, Bulfone A, Rocca PC, De Miglio MR, Orrù S.

BMC Cancer. 2018 Jan 8;18(1):56. doi: 10.1186/s12885-017-3969-y.

18.

Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.

Borgoni S, Iannello A, Cutrupi S, Allavena P, D'Incalci M, Novelli F, Cappello P.

Oncoimmunology. 2017 Nov 13;7(2):e1393596. doi: 10.1080/2162402X.2017.1393596. eCollection 2018.

19.

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.

Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A.

Clin Colorectal Cancer. 2018 Mar;17(1):80-83. doi: 10.1016/j.clcc.2017.10.017. Epub 2017 Nov 1.

PMID:
29195807
20.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A.

Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29.

PMID:
29186113
21.

Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.

Guolo F, Ferrari M, Minetto P, Matteo C, Clavio M, Coviello E, Ballerini F, Miglino M, Gobbi M, D'Incalci M, Lemoli RM, Zucchetti M.

Hematol Oncol. 2018 Apr;36(2):498-499. doi: 10.1002/hon.2484. Epub 2017 Oct 20. No abstract available.

PMID:
29052244
22.

Not only tumor but also therapy heterogeneity.

Garattini S, Fuso Nerini I, D'Incalci M.

Ann Oncol. 2018 Jan 1;29(1):13-19. doi: 10.1093/annonc/mdx646. No abstract available.

PMID:
29045538
23.

Application of 3D Mass Spectrometry Imaging to TKIs.

Morosi L, Giordano S, Falcetta F, Frapolli R, Licandro SA, Matteo C, Zucchetti M, Ubezio P, Erba E, Visentin S, D'Incalci M, Davoli E.

Clin Pharmacol Ther. 2017 Nov;102(5):748-751. doi: 10.1002/cpt.786.

PMID:
29023728
24.

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Erba E, Romano M, Gobbi M, Zucchetti M, Ferrari M, Matteo C, Panini N, Colmegna B, Caratti G, Porcu L, Fruscio R, Perlangeli MV, Mezzanzanica D, Lorusso D, Raspagliesi F, D'Incalci M.

Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4.

PMID:
28782526
25.

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.

Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M.

Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6.

26.

Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?

Tomao F, D'Incalci M, Biagioli E, Peccatori FA, Colombo N.

Cancer. 2017 Sep 15;123(18):3450-3459. doi: 10.1002/cncr.30830. Epub 2017 Jul 5. Review.

27.

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.

Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, Kalid O, Golan G, Baloglu E, Shacham S, Valsasina B, Cucchi U, Pippione AC, Lolli ML, Giabbai B, Storici P, Carloni P, Rossetti G, Benvenuti F, Bello E, D'Incalci M, Cappuzzello E, Rosato A, Del Sal G.

Nat Commun. 2017 Jun 9;8:15772. doi: 10.1038/ncomms15772.

28.

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.

Zanotti L, Romani C, Tassone L, Todeschini P, Tassi RA, Bandiera E, Damia G, Ricci F, Ardighieri L, Calza S, Marchini S, Beltrame L, Tognon G, D'Incalci M, Pecorelli S, Sartori E, Odicino F, Ravaggi A, Bignotti E.

BMC Cancer. 2017 May 25;17(1):366. doi: 10.1186/s12885-017-3334-1.

29.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

30.

Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.

Ballerini A, Moro F, Nerini IF, Marzo CM, Di Clemente A, Ferrari M, D'Incalci M, Biondi A, Colombini A, Conter V, Porcu L, Cervo L, Rizzari C, Zucchetti M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1267-1271. doi: 10.1007/s00280-017-3307-8. Epub 2017 Apr 19.

PMID:
28424964
31.

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging.

Giordano S, Pifferi V, Morosi L, Morelli M, Falciola L, Cappelletti G, Visentin S, Licandro SA, Frapolli R, Zucchetti M, Pastorelli R, Brunelli L, D'Incalci M, Davoli E.

Nanomaterials (Basel). 2017 Mar 21;7(3). pii: E71. doi: 10.3390/nano7030071.

32.

Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm.

Colmegna B, Morosi L, D'Incalci M.

Handb Exp Pharmacol. 2018;249:1-12. doi: 10.1007/164_2017_20.

PMID:
28332049
33.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
34.

Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature.

Moccia F, Fotia V, Tancredi R, Della Porta MG, Rosti V, Bonetti E, Poletto V, Marchini S, Beltrame L, Gallizzi G, Da Prada GA, Pedrazzoli P, Riccardi A, Porta C, Zambelli A, D'Incalci M.

Eur J Cancer. 2017 May;77:155-164. doi: 10.1016/j.ejca.2017.01.025. Epub 2017 Feb 28.

PMID:
28258798
35.

High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.

Coccolini F, Acocella F, Morosi L, Brizzola S, Ghiringhelli M, Ceresoli M, Davoli E, Ansaloni L, D'Incalci M, Zucchetti M.

Pharm Res. 2017 Jun;34(6):1180-1186. doi: 10.1007/s11095-017-2132-4. Epub 2017 Feb 28.

PMID:
28247168
36.

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini CM, D'Incalci M, Gatta R.

BMC Cancer. 2017 Feb 6;17(1):107. doi: 10.1186/s12885-017-3091-1.

37.

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M.

Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.

38.

Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.

Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, Tognon G, Gambino A, Calura E, Caratti G, Martini P, Beltrame L, Maragoni L, Gallo D, Odicino FE, Sartori E, Scambia G, Negrini M, Ravaggi A, D'Incalci M, Marchini S, Bignotti E, Romualdi C.

Cancer Lett. 2017 Mar 1;388:320-327. doi: 10.1016/j.canlet.2016.12.017. Epub 2016 Dec 22.

PMID:
28017893
39.

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia.

Mannarino L, Paracchini L, Craparotta I, Romano M, Marchini S, Gatta R, Erba E, Clivio L, Romualdi C, D'Incalci M, Beltrame L, Pattini L.

Pharmacogenomics J. 2018 Jan;18(1):56-63. doi: 10.1038/tpj.2016.76. Epub 2016 Dec 13.

40.

Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy.

Iori V, Iyer AM, Ravizza T, Beltrame L, Paracchini L, Marchini S, Cerovic M, Hill C, Ferrari M, Zucchetti M, Molteni M, Rossetti C, Brambilla R, Steve White H, D'Incalci M, Aronica E, Vezzani A.

Neurobiol Dis. 2017 Mar;99:12-23. doi: 10.1016/j.nbd.2016.12.007. Epub 2016 Dec 9.

PMID:
27939857
41.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda M, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M.

Oncotarget. 2017 Jan 31;8(5):7598-7613. doi: 10.18632/oncotarget.13814.

42.

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity.

Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ, Berdel WE, Burdach S.

Sarcoma. 2016;2016:7461783. Epub 2016 Oct 24.

43.

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.

Giordano S, Morosi L, Veglianese P, Licandro SA, Frapolli R, Zucchetti M, Cappelletti G, Falciola L, Pifferi V, Visentin S, D'Incalci M, Davoli E.

Sci Rep. 2016 Nov 14;6:37027. doi: 10.1038/srep37027.

44.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

45.

lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.

Martini P, Paracchini L, Caratti G, Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A, Bignotti E, Odicino FE, Sartori E, Perego P, Katsaros D, Craparotta I, Chiorino G, Cagnin S, Mannarino L, Ceppi L, Mangioni C, Ghimenti C, D'Incalci M, Marchini S, Romualdi C.

Clin Cancer Res. 2017 May 1;23(9):2356-2366. doi: 10.1158/1078-0432.CCR-16-1402. Epub 2016 Nov 8.

46.

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ.

Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3.

47.

Trabectedin as a chemotherapy option for patients with BRCA deficiency.

Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.

Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15. Review.

PMID:
27710871
48.

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Krischke M, Hempel G, Völler S, André N, D'Incalci M, Bisogno G, Köpcke W, Borowski M, Herold R, Boddy AV, Boos J.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1175-1184. doi: 10.1007/s00280-016-3174-8. Epub 2016 Oct 21.

49.

Towards a Model-Based Dose Recommendation for Doxorubicin in Children.

Völler S, Hempel G, Würthwein G, Boddy AV, Krischke M, André N, D'Incalci M, Bisogno G, Boos J.

Clin Pharmacokinet. 2017 Mar;56(3):215-223. doi: 10.1007/s40262-016-0451-y.

50.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D'Incalci M, Frapolli R.

Int J Cancer. 2017 Jan 1;140(1):197-207. doi: 10.1002/ijc.30412. Epub 2016 Sep 19.

Supplemental Content

Loading ...
Support Center